Archive for the ‘Research/Treatment’ Category

Combination therapy doubles survival in mice with mesothelioma

21 May 2018 by under Research/Treatment

research test tubes 100x100 Combination therapy doubles survival in mice with mesotheliomaCombining two cancer immunotherapy drugs – a novel immune modulator and a therapy that activates the anti-tumor immune response – more than doubled survival in laboratory mice with malignant mesothelioma, according to a report published in Cancer Immunology Research. (more…)


Immunotherapy an option for patients with recurrent pleural mesothelioma

14 May 2018 by under Research/Treatment

Diagram showing a build up of fluid in the lining of the lungs pleural effusion CRUK 0541 100x100 Immunotherapy an option for patients with recurrent pleural mesotheliomaA French study has found that immunotherapy may be effective in treating people with malignant pleural mesothelioma (MPM) that has recurred after standard chemotherapy. The treatment involved the use of two immunotherapy treatment plans – nivolumab (Opdivo) or a combination of nivolumab and ipilimumab (Yervoy). (more…)


Study to examine experimental drug in patients with pleural mesothelioma

9 May 2018 by under Research/Treatment

research test tubes 100x100 Study to examine experimental drug in patients with pleural mesotheliomaMemorial is conducting a study to determine if adding an investigational drug to standard-of-care chemotherapy is more effective at extending lifespan in patients with malignant pleural mesothelioma.

The randomized, double-blind, phase II/III study, called POLAIS2015-003, is recruiting patients with malignant with low argininosuccinate synthetase I expression. Aginine is a nutrient that makes up proteins. Laboratory studies show that ADI-PEG 20 can break down arginine, which can destroy cancer cells. Researchers want to determine if combining this experimental drug with stand-of-care chemotherapies is better than chemotherapy alone. (more…)


Experimental mesothelioma vaccine posts promising results

7 May 2018 by under Research/Treatment

syringe vaccine 100x100 Experimental mesothelioma vaccine posts promising resultsBiotech company reported positive results from a limited, Phase I/II clinical study involving its oncolytic virus platform ONCOS-102 and standard-of-care chemotherapy (pemetrexed/cisplatin) in patients with unresectable malignant pleural mesothelioma. After six months, tumor sizes were successfully reduced in three out of six patients treated with the experimental therapy. One patient had a partial response, and the disease was stable in the remaining two patients. (more…)


New guidelines support chemotherapy as first-line treatment for pleural mesothelioma

4 May 2018 by under Research/Treatment

No new drugs have been approved fDiagram showing a build up of fluid in the lining of the lungs pleural effusion CRUK 0541 100x100 New guidelines support chemotherapy as first line treatment for pleural mesotheliomaor the treatment of malignant pleural mesothelioma (MPM) since 2004, but there have been significant advances in recent years in understanding the biology of the disease and identifying new targets for therapy, the American Society of Clinical Oncology (ASCO) announced. (more…)


Novel treatment showing promise in patients with pleural mesothelioma

20 Apr 2018 by under Research/Treatment

Diagram showing a build up of fluid in the lining of the lungs pleural effusion CRUK 0541 100x100 Novel treatment showing promise in patients with pleural mesotheliomaAdding a novel therapeutic option called Tumor Treating Fields to standard of care chemotherapy demonstrated clinically meaningful improvements in overall survival and progression-free survival in patients with pleural mesothelioma, according to top-line results from Novocure’s STELLAR phase 2 pilot trial. (more…)


Majority of mesothelioma patients were exposed to asbestos

18 Apr 2018 by under Research/Treatment

800px Bauer Elementary ASBESTOS 2 100x100 Majority of mesothelioma patients were exposed to asbestosAbout 3,000 people are diagnosed with each year in the United States, and between 70 to 80 percent of them were exposed to in their lifetime. Mesothelioma is a rare and deadly form of lung cancer that affects the lining of the lungs and other organs. The disease typically kills within 18 months of diagnosis.

Asbestos is a strong, flexible mineral with fire-proof properties once commonly added to cement, insulation, roof shingles, and other products. Asbestos has been positively linked to the development of mesothelioma. (more…)


Mesothelioma study combines radiation with immunotherapy

20 Mar 2018 by under Research/Treatment
RadiationTherapy 100x100 Mesothelioma study combines radiation with immunotherapy

Credit: U.S. Air Force photo/ Staff Sgt. Liliana Moreno

Memorial Sloan Kettering in New York is recruiting patients with relapsed mesothelioma for a study to determine the safety and efficacy of a combined radiation and immunotherapy treatment.

Researchers are hoping that steroatactic body radiation therapy (SBRT) can boost the immune system’s anti- response, and that the immunotherapy drug avelumab can enhance that effect. (more…)


New mesothelioma study focuses on personalized treatment

14 Mar 2018 by under Research/Treatment

587px Researcher looks through microscope 1 100x100 New mesothelioma study focuses on personalized treatmentThe Leicester Research program, a multidisciplinary research partnership between the University of Leicester and University Hospitals of Leicester NHS trust, received a donation of about $3.5 million from the British Lung Foundation to develop a groundbreaking new umbrella study on . (more…)


Researchers identify mechanism linking mesothelioma and asbestos exposure

13 Mar 2018 by under Research/Treatment

research test tubes 100x100 Researchers identify mechanism linking mesothelioma and asbestos exposureA team of researchers has found the exact mechanism that causes malignant mesothelioma, a rare and deadly form of cancer linked to exposure.

According to a study by the Swiss National Science Foundation, malignant begins when the long, pointed fibers of asbestos come in contact with the cells of the mesothelium, the membrane that covers the lungs and other organs. The body is unable to expel the fibers through the lymphatic system, leaving them to wreak havoc on tissue creating micro injuries. This causes an immune reaction, triggering white blood cells to rush to the site of the injury to repair the tissue. But, the cells multiply so quickly that tumors form and the cells’ RNA mutates, creating the perfect landscape for the cancer to grow out of control. (more…)